TickerFacts.

Compare

Apimeds Pharmaceuticals US, Inc. vs Transcode Therapeutics, Inc. vs Gyre Therapeutics, Inc. vs Climb Bio, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearApimeds Pharmaceuticals US, Inc.
APUS		Transcode Therapeutics, Inc.
RNAZ		Gyre Therapeutics, Inc.
GYRE		Climb Bio, Inc.
CLYM
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenuen/an/a$116.59Mn/a
Revenue growth (YoY)n/an/a+10.2%n/a
Gross marginn/an/an/an/a
Operating marginn/an/a9.9%n/a
Net marginn/an/a8.5%n/a
Net income-$6.00M-$34.66M$9.88M-$59.85M
EPS (Diluted)-$0.55-$52.59$0.02-$0.88
Operating cash flow-$8.93M-$19.52M$1.01M-$54.36M
Free cash flow-$8.98M-$19.52M-$180.0K-$54.54M
Cash & equivalents$1.64M$17.81M$37.07M$35.69M
Total assets$164.18M$162.40M$166.13M$167.74M
Total liabilities$10.84M$10.52M$23.85M$7.27M
Shareholders' equity$153.35M$10.34M$106.03M$160.47M
Return on year-end equity-3.9%-335.4%9.3%-37.3%
Shares outstanding12.58M917.0K91.31M47.77M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearApimeds Pharmaceuticals US, Inc.Transcode Therapeutics, Inc.Gyre Therapeutics, Inc.Climb Bio, Inc.
Latestn/an/a$116.59M
Ended 2025-12-31		n/a
1 year earliern/an/a$105.76M
Ended 2024-12-31		n/a
2 years earliern/an/a$113.45M
Ended 2023-12-31		n/a
3 years earliern/an/a$102.29M
Ended 2022-12-31		n/a
4 years earliern/an/a$7.34M
Ended 2021-12-31		n/a